Compare Coursera Inc (COUR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs TG Therapeutics Inc — how do they compare? Coursera Inc trades at $5.2 (market cap $1.39B), while TG Therapeutics Inc trades at $54.98 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 5.9× Coursera Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and TG Therapeutics Inc for 16 Days on average.
| COUR | TGTX | |
|---|---|---|
Market Cap | $1.39B | $8.16B |
Volume | 9,728,980 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $59.06 |
52-Week Low | $4.64 | $26.94 |
Typical Hold Time | 47 Days | 16 Days |
Enterprise Value | $648.49M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.235, up 2.45% today, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. Revenue has grown steadily from $524M in 2022 to $758M in 2025, though the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights strong institutional interest, including a 137% surge in call option volume (Defense World, 2026-10-01) and the launch of Project Helix, an AI-native learning platform (Business Wire, 2026-09-09).
The stock offers upside to the $7.40 analyst consensus target but faces risks from persistent losses and integration challenges. Positive cash flow and subscriber growth are key strengths, yet profitability remains elusive. Investors should weigh the 52.94% buy rating against high RSI levels and competitive pressures in the edtech sector.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
